Tume Sebastian C, Fuentes-Baldemar Andres A, Anders Marc, Spinner Joseph A, Tunuguntla Hari, Imamura Michiaki, Razavi Asma, Hickey Edward, Stapleton Gary, Qureshi Athar M, Adachi Iki
Division of Pediatric Critical Care Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, Tex.
Division of Congenital Heart Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, Tex.
J Thorac Cardiovasc Surg. 2023 Dec;166(6):1756-1763.e2. doi: 10.1016/j.jtcvs.2022.11.039. Epub 2022 Dec 24.
We report the largest pediatric single-center experience with an Impella (Abiomed Inc) catheter-based axial pump support.
We conducted a retrospective cohort study of all patients with acute decompensated heart failure or cardiogenic shock requiring catheter-based axial pump support between October 2014 and February 2022. The primary outcome per individual encounter (hospital admission) was defined as bridge-to-recovery, bridge-to-durable ventricular assist device support, bridge-to-cardiac transplantation, or death at 6 months after catheter-based axial pump explantation. Adverse events were defined according to the Pediatric Interagency Registry for Mechanical Circulatory Support criteria.
Our final study cohort included 37 encounters with 43 catheter-based axial pump implantations. A single catheter-based axial pump device was used for support in 33 encounters (89%), with 2 catheter-based axial pump devices used in 3 (8%) separate encounters and 3 catheter-based axial pump devices used in 1 (3%) encounter. The median [range] age, weight, and body surface area at implantation were 16.8 [6.9-42.8] years, 61.1 [23.1-123.8] kg, and 1.7 [0.8-2.5] m, respectively. The predominant causes of circulatory failure were graft failure/rejection in 16 patients (43%), followed by cardiomyopathy in 7 patients (19%), arrhythmia refractory to medical therapies in 6 patients (16%), myocarditis/endocarditis in 4 patients (11%), and heart failure due to congenital heart disease in 4 patients (11%). Competing outcomes analysis showed a positive outcome with bridge-to-recovery in 58%, bridge-to-durable VAD support in 14%, and bridge-to-cardiac transplantation in 14% at 6 months. Fourteen percent of encounters resulted in death at 6 months.
We demonstrate that catheter-based axial pump support in children results in excellent 1- and 6-month survival with an acceptable adverse event profile.
我们报告了使用Impella(Abiomed公司)基于导管的轴流泵支持的最大规模儿科单中心经验。
我们对2014年10月至2022年2月期间所有因急性失代偿性心力衰竭或心源性休克而需要基于导管的轴流泵支持的患者进行了一项回顾性队列研究。每次就诊(住院)的主要结局定义为恢复、过渡到持久心室辅助装置支持、过渡到心脏移植或在基于导管的轴流泵取出后6个月时死亡。不良事件根据儿科机械循环支持跨机构登记标准进行定义。
我们的最终研究队列包括37次就诊,进行了43次基于导管的轴流泵植入。33次就诊(89%)使用单个基于导管的轴流泵装置进行支持,3次(8%)单独就诊使用2个基于导管的轴流泵装置,1次(3%)就诊使用3个基于导管的轴流泵装置。植入时的中位[范围]年龄、体重和体表面积分别为16.8[6.9 - 42.8]岁、61.1[23.1 - 123.8]kg和1.7[0.8 - 2.5]m²。循环衰竭的主要原因是移植物失败/排斥16例(43%),其次是心肌病7例(19%),药物治疗无效的心律失常6例(16%),心肌炎/心内膜炎4例(11%),先天性心脏病导致的心力衰竭4例(11%)。竞争结局分析显示,6个月时恢复的阳性结局为58%,过渡到持久心室辅助装置支持为14%,过渡到心脏移植为14%。14%的就诊在6个月时导致死亡。
我们证明,儿童基于导管的轴流泵支持可带来良好的1个月和6个月生存率,不良事件情况可接受。